Related references
Note: Only part of the references are listed.T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors
Mouldy Sioud
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2018)
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
Junzo Hamanishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Single-Institution Experience With Ipilimumab in Advanced Melanoma Patients in the Compassionate Use Setting Lymphocyte Count After 2 Doses Correlates With Survival
Geoffrey Y. Ku et al.
CANCER (2010)
PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells
Y Iwai et al.
INTERNATIONAL IMMUNOLOGY (2005)
Share Paper
